Navigation Links
Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Date:1/16/2013

Las Vegas (PRWEB) January 16, 2013

Convoy Therapeutics, a subsidiary of ACTUS Biotechnologies, is proud to announce the relaunching of their website. The revised website includes new information regarding the company's platform technology and development programs.

The interactive website provides a user-friendly platform for interested parties to gather information regarding Convoy Therapeutics’ innovative platform technology and its various uses in enabling the penetration of macromolecules and retention of small molecules in the skin for a wide variety of cosmetic and therapeutic uses.
“The revamped website offers comprehensive information regarding Convoy’s ground-breaking technology and how it can be applied in a variety of uses in cosmetic and therapeutic applications,” says Dr. Robert Davis, Chief Business Officer of Convoy Therapeutics. “Perhaps more importantly, it shows the incredible healing opportunities possible when combining other therapies with our skin-penetrating technologies.” Convoy Therapeutics’ main objective is to provide a platform for effective and efficient drug, cosmeceutical, or active delivery into the skin. “The website demonstrates the difference between the previous systems of skin delivery and Convoy’s technology,” adds Dr. Davis.

The newly designed website includes diagrams, videos, and slide presentations that visually demonstrate the Convoy technology penetrating the outer layers of the skin, delivering therapeutic macromolecules. Treatment areas include: dermatology, immunology, vaccinations, and cancer. The website also contains information regarding the company's development pipeline including: CY-102, a reformulated Cyclosporine for topical use in treating psoriasis currently in late stage development, and HA-102PH, a topical cosmetic preparation of hyaluronic acid for enhanced skin tone and hydration also in the later development stages.

The website also provides information on Convoy Therapeutics’ acting Executive Management team, its Chief Scientific Advisor and inventor of the technology, Professor Samir Mitragotri, as well as a video by Professor Mitragotri discussing Convoy Therapeutics’ innovative platform technology.

To find out more about Convoy Therapeutics, please visit our new designed website at http://www.convoytx.com, or contact us at (702) 448-1826.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10321618.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):